Stock fact sheet · data as of
Aytu BioPharma, Inc. (AYTU): fair value, margin of safety and Wheel Score
Ticker symbol AYTU · Healthcare · Drug Manufacturers - Specialty & Generic · United States · Speculative
Is AYTU undervalued?
At 1.92 (close of 5 Nov 2026), AYTU trades 64% below the GLS average fair value of 5.29. That average comes from 1 models run on the latest filings, and 1 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Aytu BioPharma, Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
The average is built from just 1 models (10 Cap) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files AYTU under Speculative - it is losing money or its Piotroski health score is 3 or lower - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for AYTU
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 5.29 | +176% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -0.7336 | -138% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Aytu BioPharma, Inc. scores only 4 of 9 on the Piotroski F-score, which fails the "Piotroski 6 or more" Wheel Trade Filter. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 2.8/10 is a weak reading: the accounts do not show returns and margins that competitors have been unable to wear down, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -26.7%, ROE -40.4%, ROA -13.6% - with debt at 0.51 times equity and a free-cash-flow yield of 15.6%.
Aytu BioPharma, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Consumer Health 100% (quarter Q4 FY2024).
Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | -26.7% |
|---|---|---|---|
| GLS Moat | 2.8 / 10 | ROE | -40.4% |
| Debt / equity | 0.51 | ROA | -13.6% |
| Free-cash-flow yield | 15.6% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 28: No options
No options are listed on Aytu BioPharma, Inc. in our nightly snapshot, so it fails the first Wheel Trade Filter (options that actually trade) (it reads 28, under 70) and is left out of every options scan; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 28k shares a day on a market cap of $21M, with a beta of 0.27 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | no listed options |
| 2 | A real business, not a gamble | Fails | speculative (a loss, or a weak Piotroski score) |
| 3 | Below fair value | Passes | Trading below the nine-model average fair value (margin of safety above 0) |
| 4 | Financially healthy | Fails | Piotroski 4/9 (under 6) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | no implied volatility |
| 8 | Big enough | Fails | market cap $21M (under $1.0B) |
| 9 | Not a penny stock | Fails | price 1.92 (under $5) |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Strong | 64% below fair value | |
| Premium | Weak | no option data | |
| Moat | Weak | moat 2.8/10 | |
| Health | Fair | Piotroski 4/9 | |
| Red Flags | Fair | not scored yet - half marks | |
| Option trading | Weak | no option volume data | |
| Stability | Fair | beta 0.27, $21M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
Aytu BioPharma, Inc. reports earnings on 12 Nov 2026 (after the close) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
No analyst upgrades or downgrades were recorded in the last 30 days.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Aytu BioPharma, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| TXMD TherapeuticsMD, Inc. | 1.82 | 5.39 | +66% | 28Weak | $21M |
| HYEX Healthy Extracts Inc. | 1.40 | 0.6122 | -129% | 12No options | $21M |
| BIOE Bio Essence Corporation | 0.4700 | 0.8646 | +46% | 27No options | $19M |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | 5.21 | - | - | 10No options | $25M |
| CPHI China Pharma Holdings, Inc. | 0.5875 | - | - | 12No options | $25M |
| HSTI High Sierra Technologies, Inc. | 1.40 | - | - | 11No options | $29M |
| RAPH Raphael Pharmaceutical Inc. | 1.51 | - | - | 8No options | $30M |
| RMTI Rockwell Medical, Inc. | 8.05 | 9.84 | +18% | 17Weak | $32M |
| OPTH Optimi Health Corp. | 2.21 | - | - | 11No options | $13M |
| EGRX Eagle Pharmaceuticals, Inc. | 0.9500 | 62.37 | +98% | 32No options | $12M |
| INCR InterCure Ltd. | 3.61 | 1.71 | -111% | 13Weak | $43M |
| INM InMed Pharmaceuticals Inc. | 1.75 | - | - | 11No options | $10M |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about AYTU
Is AYTU undervalued right now?
By the GLS models, yes: at 1.92 the stock is 64% below the average fair value of 5.29 (data as of 5 Nov 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of AYTU and what does it mean?
AYTU has no listed options in our nightly snapshot, so it cannot be wheeled; it fails the first Wheel Trade Filter (options that actually trade), stays under 70 and is shown as "No options".
What is the GLS fair value for AYTU?
5.29 per share as of 5 Nov 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Aytu BioPharma, Inc. report earnings next?
The next earnings report is due on 12 Nov 2026 (after the close), 7 days from the data date of 5 Nov 2026. The Calendars page lists every upcoming report with its time of day.
Does AYTU have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on AYTU, so the wheel strategy cannot be run on it and the Wheel Score stays under 70.